+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 151 Actively Recruiting clinical trials

I

Actively Recruiting

Researchers are investigating treatments for oligodendrogliomas, a type of brain tumor classified by specific genetic markers including mutations in isocitrate dehydrogenase IDH and co-deletion of chromosomes 1p19q. This trial focuses on adults with newly diagnosed grade 2 or 3 gliomas, aiming to improve survival without loss of brain function, cognition, or quality of life. The study compares two treatment approaches to determine the best timing and combination of chemotherapy and radiotherapy. Participants are randomly assigned to receive either standard chemoradiation with procarbazine, CCNU lomustine, and vincristine PCV combined with radiotherapy, or an experimental approach starting with chemotherapy using lomustine and temozolomide CETEG followed by radiotherapy and PCV at tumor progression. Radiotherapy is delivered over about 5 to 6 weeks, with doses adjusted for tumor grade. Chemotherapy cycles last 6 weeks and include specified doses of oral and intravenous drugs. During the study, participants undergo regular magnetic resonance imaging MRI scans every three months, neurological assessments, quality of life questionnaires, and cognitive testing annually. The main outcome measured is qualified overall survival, which tracks survival without significant cognitive or functional decline. The study lasts up to 10 years, with ongoing monitoring of tumor progression, treatment response, and patient wellbeing. Safety and side effects are carefully assessed throughout the trial.

Age: 18Years +All GendersPhase 3
19 locations
C

Actively Recruiting

Researchers are evaluating the efficacy and safety of rilvegostomig compared to pembrolizumab, both combined with platinum-based doublet chemotherapy, as a first-line treatment for patients with locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC whose tumors express PD-L1 at 1% or higher. This Phase III, randomized, double-blind, global study focuses on patients without certain genetic mutations who have advanced disease not suitable for curative treatment. The trial aims to provide new treatment options for this patient group by comparing two immunotherapy approaches combined with chemotherapy. Participants receive either rilvegostomig or pembrolizumab, each given intravenously on Day 1 of every 21-day cycle, alongside platinum-based doublet chemotherapy carboplatin or cisplatin for up to four cycles. After chemotherapy, patients continue with maintenance monotherapy of their assigned immunotherapy rilvegostomig or pembrolizumab plus pemetrexed given intravenously on Day 1 of each 21-day cycle. This treatment continues until disease progression or unacceptable toxicity. Throughout the study, participants undergo regular assessments including tumor measurements by CT or MRI scans, organ and bone marrow function tests, and monitoring for side effects. Researchers will measure overall survival and progression-free survival for up to approximately six years. Patient-reported outcomes on physical functioning, quality of life, and lung cancer symptoms are also collected. Safety and pharmacokinetics of rilvegostomig are monitored to understand treatment effects and tolerability over the long term.

Age: 18Years +All GendersPhase 3
301 locations
G

Actively Recruiting

Researchers are evaluating the safety and effectiveness of rilvegostomig combined with platinum-based chemotherapy compared to pembrolizumab combined with the same chemotherapy for first-line treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer mNSCLC whose tumors express PD-L1. This Phase III, randomized, double-blind study involves participants whose tumors have a PD-L1 expression of 1% or higher. Participants receive either rilvegostomig or pembrolizumab intravenously on Day 1 of each 21-day cycle, combined with carboplatin and paclitaxel or nab-paclitaxel chemotherapy. Chemotherapy is given for up to 4 cycles, with nab-paclitaxel administered on Days 1, 8, and 15 of each cycle. After the chemotherapy cycles, participants continue with the assigned drug alone. Throughout the study, researchers monitor overall survival and progression-free survival for up to approximately six years. Additional assessments include response rates, duration of response, drug levels in the body, immune reactions to rilvegostomig, and patient-reported physical functioning, quality of life, and lung cancer symptoms. Participants undergo regular evaluations to assess these outcomes and safety throughout the study period.

Age: 18Years +All GendersPhase 3
333 locations
O

Actively Recruiting

This observational study follows patients with relapsing multiple sclerosis RMS who are being treated with approved injectable or selected oral disease-modifying therapies DMTs in Germany. The study is non-interventional and open-label, designed to collect real-world data on treatment and disease progression over several years. It aims to understand how patients continue their baseline treatments and how these treatments impact various health and quality of life measures. Participants receive routine medical care with approved injectable or oral DMTs such as ofatumumab, interferon b21, glatiramer acetate, teriflunomide, dimethyl fumarate, or diroximel fumarate. The study includes two cohorts with up to approximately two years of prospective observation each, with an optional extension allowing up to four years total. Treatment decisions and monitoring follow the patients usual care and physicians discretion, including routine visits and telemedicine options. During the study, participants provide medical history, complete questionnaires, and have data collected on disability status, MRI findings, relapses, and laboratory tests. Researchers assess treatment continuation rates, fatigue, anxiety, depression, quality of life, lesion counts, and relapse rates at multiple time points. Safety and treatment interruptions are also documented. Follow-up is flexible and based on standard care procedures, with data collection occurring throughout the observational periods.

Age: 18Years - 100YearsAll Genders
141 locations
O

Actively Recruiting

Researchers are evaluating the real-world effectiveness, safety, and patient compliance of ribociclib combined with an aromatase inhibitor for adjuvant treatment in patients with hormone receptor-positive, HER2-negative early breast cancer at high risk of recurrence. This observational study also compares ribociclib treatment with abemaciclib plus endocrine therapy and endocrine therapy alone, aiming to better understand treatment decisions and clinical adoption in routine practice. The study is conducted across breast centers and gynecological practices to represent typical healthcare settings. Participants receive treatment based on their physicians clinical judgment without randomization or intervention assignment. The study collects data from patients treated with ribociclib plus aromatase inhibitor with or without luteinizing hormone-releasing hormone LHRH, abemaciclib plus endocrine therapy with or without LHRH, or endocrine therapy alone with or without LHRH. Baseline data and follow-up information on adverse events, quality of life, treatment adherence, and socio-economic factors are gathered over time. During the study, participants undergo assessments including evaluation of invasive disease-free survival up to 36 months, quality of life questionnaires, medication adherence reports, and monitoring of adverse events and treatment changes. Data on reasons for treatment decisions, patient perceptions, and healthcare provider involvement are also collected. The study duration extends up to 39 months to provide a comprehensive overview of treatment impact and patient experience in real-world clinical settings.

Age: 18Years - 100YearsAll Genders
287 locations
P

Actively Recruiting

Researchers are evaluating the safety and effects of a medicine called Fosmanogepix for treating candidemia and invasive candidiasis, serious fungal infections caused by Candida species. This Phase 3 study compares Fosmanogepix with standard treatments to see if it works at least as well as current therapies. The trial involves adult patients diagnosed with these infections, aiming to assess treatment success and patient survival. Participants receive one of two treatments two-thirds get Fosmanogepix through an intravenous IV infusion daily at the clinic, with an option to switch to oral tablets if well enough to continue treatment at home. One-third receive the standard care of Caspofungin IV infusion followed by oral Fluconazole capsules. Matching placebos are used for blinding. Treatment can last up to 6 weeks depending on infection clearance and symptom improvement. During the study, participants undergo regular assessments including blood tests and monitoring for treatment success and safety. Researchers measure survival at 30 days and response rates at multiple time points, including after treatment ends and at a 6-week follow-up. The study tracks adverse events, lab abnormalities, and drug levels to evaluate safety and treatment effects. Total participation can last up to about 12.5 weeks with follow-up visits to monitor long-term outcomes.

Age: 18Years +All GendersPhase 3
146 locations
P

Actively Recruiting

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.

Age: 18Years +All GendersPhase 3
1452 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of rilvegostomig combined with fluoropyrimidine and trastuzumab deruxtecan T-DXd compared to trastuzumab, chemotherapy, and pembrolizumab in participants with HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 combined positive score CPS of 1 or higher. This Phase 3, randomized, open-label study also includes a separate group receiving rilvegostomig with trastuzumab and chemotherapy to understand the contribution of each treatment component. The study is being conducted globally across many sites in about 25 countries. Participants are assigned to one of three treatment groups Arm A receives rilvegostomig, fluoropyrimidine capecitabine or 5-fluorouracil, and trastuzumab deruxtecan Arm B receives pembrolizumab, trastuzumab, and chemotherapy 5-fluorouracil plus cisplatin or capecitabine plus oxaliplatin Arm C receives rilvegostomig, trastuzumab, and chemotherapy. Treatments are administered mainly through intravenous infusions every three weeks, with capecitabine taken orally twice daily. The study aims to assess the role of each treatment combination over time. During the study, participants will undergo regular assessments including tumor measurements, safety checks for adverse events, and blood tests to monitor drug levels and immune responses. Researchers will track progression-free survival and overall survival for up to six years, along with response rates and treatment side effects. The study includes ongoing monitoring for eating difficulties and side-effect impact. Participants will be followed closely throughout treatment and for years afterward to evaluate long-term outcomes and safety.

Age: 18Years +All GendersPhase 3
304 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of new combinations of treatments, including novel drugs and standard therapies, for patients with advanced or metastatic non-small cell lung cancer NSCLC. This multicenter, open-label study focuses on participants with stage IV NSCLC, specifically assessing combinations involving rilvegostomig with platinum-based chemotherapy and with or without ramucirumab. The study includes a sub-study with safety and dose expansion phases to identify the recommended dose and assess treatment activity. Participants with squamous and non-squamous NSCLC will receive intravenous infusions of rilvegostomig combined with standard chemotherapy drugs such as cisplatin, carboplatin, pemetrexed, paclitaxel, or nab-paclitaxel. Some participants will also receive ramucirumab as part of their treatment. The sub-study consists of a Part A safety run-in to evaluate dose levels and a Part B expansion phase to further study the treatments. Participants are randomized into different treatment arms depending on their cancer histology. During the study, participants will undergo monitoring for adverse events, dose-limiting toxicities, and tumor response over approximately 46 months. Assessments include measuring objective response, duration and time to response, disease control, progression-free survival, overall survival, and various blood drug concentration parameters. Tumor tissue samples are required for evaluation, and safety and tolerability are closely monitored throughout the treatment period.

Age: 18Years +All GendersPhase 1Phase 2
103 locations
O

Actively Recruiting

Researchers are evaluating denecimig Mim8 for adults diagnosed with acquired haemophilia A, a rare bleeding disorder. This Phase 3 open-label study aims to assess the safety and effectiveness of denecimig in reducing bleeding episodes in this population. The study is sponsored by Novo Nordisk AS and will follow participants for up to about one year and five months. Participants will receive subcutaneous injections of denecimig during the study. The treatment period includes a main part lasting 12 weeks followed by an extension phase up to 52 weeks. Denecimig plasma levels and the occurrence of antidrug antibodies will be monitored throughout the treatment. The study also tracks bleeding events and the use of other bleeding management therapies. During the study, participants will be closely monitored for treated and clinically relevant bleeding episodes, infections, and immune responses. The primary outcome is the number of treated bleeds during the first 12 weeks of treatment. Secondary outcomes include bleeding frequency, treatment days with bypassing agents or factor VIII products, and denecimig plasma concentration over one year. Participants are expected to follow study procedures and seek medical attention as needed during the approximately 73-week study period.

Age: 18Years +All GendersPhase 3
83 locations

1-10 of 151

1